News | Pharmaceuticals | September 11, 2017

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib

Investigational medicine for cardiovascular disease significantly reduced risk of major coronary events when combined with statin therapy

Merck Announces Results of REVEAL Outcomes Study of Anacetrapib

September 11, 2017 — Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and presentation of results from the REVEAL outcomes study of anacetrapib, Merck’s investigational cholesteryl ester transfer protein (CETP) inhibitor. In the study of 30,449 patients with atherosclerotic vascular disease receiving LDL-C lowering treatment with atorvastatin, anacetrapib significantly reduced the risk of major coronary events (composite of coronary death, myocardial infarction or coronary revascularization) by 9 percent relative to placebo (10.8% vs. 11.8%, respectively; P=0.004). The safety of anacetrapib was generally consistent with data from earlier trials of the drug. However, a sub-study also showed that anacetrapib accumulates in adipose tissue with prolonged dosing.

Merck is reviewing the results of the trial with external experts and will consider whether to file new drug applications with the U.S. Food and Drug Administration (FDA) and other regulatory agencies.

The results of REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) were presented by Martin Landray, MB, ChB, Ph.D., of the University of Oxford, the trial’s co-principal investigator, during a late-breaking clinical trials session at the European Society of Cardiology Congress, Aug. 26-30 in Barcelona, Spain, and simultaneously published in the online edition of The New England Journal of Medicine.

REVEAL was designed and independently conducted by investigators at the Clinical Trial Service Unit at the University of Oxford, the trial’s regulatory sponsor, in collaboration with the TIMI Study Group based at Brigham and Women’s Hospital in Boston and Merck. Merck provided funding for REVEAL.

In the randomized, double-blind, placebo-controlled clinical study, 30,449 adults with atherosclerotic vascular disease on study-mandated intensive atorvastatin therapy (mean baseline LDL cholesterol level 61 mg/dL [1.58 mmol/L], non-HDL cholesterol 92 mg/dL [2.38 mmol/L], and HDL cholesterol 40 mg/dL [1.03 mg/dL]) were randomly assigned to receive either anacetrapib 100 mg once daily or matching placebo. The primary assessment was an intention-to-treat comparison among all randomized participants of the effect of anacetrapib on the composite of major coronary events, defined as the first occurrence of coronary death, myocardial infarction or coronary revascularization.

Compared with placebo, the addition of anacetrapib further reduced the mean level of non-HDL cholesterol by 17 mg/dL (0.44 mmol/L,18%) and increased HDL cholesterol level by 43 mg/dL (1.12 mmol/L, 104%) at the study midpoint. During median follow-up of 4.1 years, a 9 percent relative reduction in the risk of major coronary events was observed among those receiving anacetrapib compared to placebo (1640 events [10.8%] versus 1,803 events [11.8%]; rate ratio 0.91; 95% CI 0.85 to 0.97; P=0.004). The benefit was similar across multiple pre-specified subgroups.

The difference in the key secondary composite outcome of major atherosclerotic events (myocardial infarction, coronary death or presumed ischemic stroke) did not reach statistical significance (rate ratio, 0.93; 95% CI, 0.86 to 1.00; P=0.052), possibly due to a lack of observed benefit of anacetrapib on presumed ischemic stroke. There were no statistically significant differences in cause-specific mortality, cancer or other serious adverse events. Anacetrapib produced small increases in systolic and diastolic blood pressures of 0.7 mmHg and 0.3 mmHg, respectively; there was no statistically significant increase of serious adverse events attributed to hypertension. Compared to those receiving placebo, more patients in the anacetrapib group developed an estimated glomerular filtration rate of less than 60 ml/min/1.73m2 by the end of the study (11.5% vs. 10.6%; P=0.04); there was no statistically significant impact on the development of albuminuria or serious adverse events attributed to renal failure.

For more information: www.escardio.org

Related Content

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

The first 3-D images have been created of an RNA molecule known as "Braveheart" for its role in transforming stem cells into heart cells. Credit: Image courtesy Los Alamos National Laboratory

News | Cardiovascular Clinical Studies | January 20, 2020
January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special
Top Cardiology New in 2019 From the European Society of Cardioloigy (ESC)
News | Cardiovascular Clinical Studies | December 23, 2019
Environmental and lifestyle issues were popular this year, with pick up from both...
News | Cardiovascular Clinical Studies | November 26, 2019
November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have sele
FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo